Luis F. Parada

Luis F. Parada

Auto-generated profile, based on publicly available information

Luis F. Parada

Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in Nature
Verified
Journal Article
Open access
PDF file
JCJian Chen
Jian Chen
YLYanjiao Li
Yanjiao Li
TYTzong-Shiue Yu
Tzong-Shiue Yu
RMRenée M. McKay
Renée M. McKay
DBDennis K. Burns
Dennis K. Burns
LPLuis F. Parada
Luis F. Parada
By using a GFP reporter protein expressed selectively in neural stem cells in a mouse model of glioblastoma, a small subset of GFP-positive glioma cells is shown to be responsible for re-growth of tumours after chemotherapy. In a mouse model of glioblastoma, Luis Parada and colleagues use a green fluorescent protein (GFP) reporter protein expressed selectively in neural stem cells — in which the tumours arise — to trace cancer cells in an endogenous setting. The reporter labelled a small subset of glioma cells that were less proliferative than the bulk of the tumour cells. However, the GFP+ cells were responsible for re-growth of the tumours after treatment with the cytotoxic drug temozolomide. Selective ablation of the GFP+ cells combined with temozolomide was more effective at arresting tumour growth. The GFP+ cells appear to be at the apex of a functional hierarchy of cancer cells so may represent cancer stem cells — a subset of tumour cells able to maintain tumour growth. Targeting both this population and the more proliferative bulk of cancer cells may lead to improved therapeutic outcome. Glioblastoma multiforme is the most common primary malignant brain tumour, with a median survival of about one year1. This poor prognosis is due to therapeutic resistance and tumour recurrence after surgical removal. Precisely how recurrence occurs is unknown. Using a genetically engineered mouse model of glioma, here we identify a subset of endogenous tumour cells that are the source of new tumour cells after the drug temozolomide (TMZ) is administered to transiently arrest tumour growth. A nestin-ΔTK-IRES-GFP (Nes-ΔTK-GFP) transgene that labels quiescent subventricular zone adult neural stem cells also labels a subset of endogenous glioma tumour cells. On arrest of tumour cell proliferation with TMZ, pulse-chase experiments demonstrate a tumour re-growth cell hierarchy originating with the Nes-ΔTK-GFP transgene subpopulation. Ablation of the GFP+ cells with chronic ganciclovir administration significantly arrested tumour growth, and combined TMZ and ganciclovir treatment impeded tumour development. Thus, a relatively quiescent subset of endogenous glioma cells, with properties similar to those proposed for cancer stem cells, is responsible for sustaining long-term tumour growth through the production of transient populations of highly proliferative cells.

1 May 2006 in Neuron
Verified
Journal Article
Closed access
CKChang-Hyuk Kwon
Chang-Hyuk Kwon
BLBryan W. Luikart
Bryan W. Luikart
CPCraig Powell
Craig Powell
JZJing Zhou
Jing Zhou
SMSharon A. Matheny
Sharon A. Matheny
LPLuis F. Parada
Luis F. Parada

1 January 2009 in Cancer Cell
Verified
Journal Article
Closed access
SLSheila Alcantara Llaguno
Sheila Alcantara Llaguno
JCJian Chen
Jian Chen
CKChang-Hyuk Kwon
Chang-Hyuk Kwon
EJErica L. Jackson
Erica L. Jackson
YLYanjiao Li
Yanjiao Li
LPLuis F. Parada
Luis F. Parada

1 August 2008 in Neuron
Verified
Journal Article
Closed access
YLYun Li
Yun Li
BLBryan W. Luikart
Bryan W. Luikart
SBShari Birnbaum
Shari Birnbaum
JCJian Chen
Jian Chen
CKChang-Hyuk Kwon
Chang-Hyuk Kwon
LPLuis F. Parada
Luis F. Parada

3 May 2002 in Science
Verified
Journal Article
Closed access
YZYuan Zhu
Yuan Zhu
PGPritam Ghosh
Pritam Ghosh
PCPatrick Charnay
Patrick Charnay
DBDennis K. Burns
Dennis K. Burns
LPLuis F. Parada
Luis F. Parada
Neurofibromatosis type 1 (NF1) is one of the most prevalent dominantly inherited genetic diseases of the nervous system. NF1 encodes a tumor suppressor whose functional loss results in the development of benign neurofibromas that can progress to malignancy. Neurofibromas are complex tumors composed of axonal processes, Schwann cells, fibroblasts, perineurial cells, and mast cells. Through use of a conditional ( cre / lox ) allele, we show that loss of NF1 in the Schwann cell lineage is sufficient to generate tumors. In addition, complete NF1-mediated tumorigenicity requires both a loss of NF1 in cells destined to become neoplastic as well as heterozygosity in non-neoplastic cells. The requirement for a permissive haploinsufficient environment to allow tumorigenesis may have therapeutic implications for NF1 and other familial cancers.

1 March 2012 in Cell
Verified
Journal Article
Closed access
JCJian Chen
Jian Chen
RMRenée M. McKay
Renée M. McKay
LPLuis F. Parada
Luis F. Parada